JAZZ

Jazz Pharmaceuticals plc NMS · JAZZ

$251.24 +7.77 (+3.19%)

Extended · +1.49σ

+ Compare Open in Sniper

Mkt cap $15.8B

P/E 2093.6

Day $242.11 – $251.44

52wk $161.38 – $251.44

Avg vol 0.9M

Beta 0.32

Div yld —

Next earnings 2026-08-03

Quick read

Plain English

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

JAZZ last traded at $251.24, up 3.2% on the day; that's in the upper part of its 52-week range ($161.38–$251.44). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

The next scheduled earnings report (2026-08-03) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC1 upper, +1.49 ATR from EMA21 — no notable pattern

Long —

score 12 · tech 12 / 80 · support 0 / 20

above KC1 lower, +1.49 ATR from EMA21 · no notable pattern

· Aligned with weak uptrend

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 17 · tech 17 / 80 · support 0 / 20

KC1 upper, +1.49 ATR from EMA21 · no notable pattern

· KC1 upper stretch — light pop

How this grade was earned

total 17 pts

Cycle position 14

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $803.90 (fair range $2–$804); today's price leaves a +69% cushion below that estimate. The model's verdict is “Deep value” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$803.90

Fair-value range

$1.80 – $803.90

Margin of safety

+69%

Verdict

Deep value

Accounting quality Weak

✓ Quick ratio 1.65 (antifragile)
✓ Positive retained earnings
✓ Gross margin 92% (pricing power)

⚠ Debt exceeds cash
⚠ Receivables growing faster than revenue

Price implies ~1% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

JAZZ is a $15.8 billion company, priced at 2094× last year's earnings, and it moves more calmly than the market (beta 0.3); the stock is trading near the top of its 52-week range.

Mkt cap $15.8B

P/E ttm 2093.6

Fwd P/E 9.8

Beta 0.32

Day range $242.11 – $251.44

52w range $161.38 – $251.44

Avg vol 0.9M

RSI(2) 81.6

ROE 0.7%

Net mgn 0.7%

FCF mgn 30.1%

Debt/Eq 1.20

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-03

52-week range · today's price

$161.38$251.44

More on JAZZ

Options idea

See more →

CALL $250 2026-08-21

$11.77

PUT $250 2026-08-21

$0.00

Earnings

See more →

Last reported: 2026-05-05
EPS (act / est): 6.34 / 4.66
Surprise: +36.2%
Next report: 2026-08-03

About

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous scle…